Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology

Core Insights - Defence Therapeutics Inc. has received a Notice of Allowance from the USPTO for its U.S. patent application covering next-generation antibody-drug conjugate (ADC) technology, which includes broad composition-of-matter claims for therapeutically active ADCs [1][2] - The allowed patent application (no. 18/351,291) will potentially grant the company market exclusivity for its proprietary second-generation Accum®-based ADCs until 2043 [2][4] - The company has an established patent portfolio for its Accum® technology, with granted patents in the U.S., Japan, Australia, and Israel, and pending applications in Canada and Europe [3][4] Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation ADC products using its proprietary Accum® technology, which enhances the precision delivery of ADCs to target cells [5] - The Accum® technology aims to increase the efficacy and potency of cancer treatments [5]